Enanta Pharmaceuticals
ENTA
ENTA
195 hedge funds and large institutions have $1.7B invested in Enanta Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
4.86% more ownership
Funds ownership: 86.75% → 91.61% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
32% less call options, than puts
Call options by funds: $5.14M | Put options by funds: $7.51M
Holders
195
Holding in Top 10
3
Calls
$5.14M
Puts
$7.51M
Top Buyers
| 1 | +$28.2M | |
| 2 | +$24.6M | |
| 3 | +$22.8M | |
| 4 |
O
OrbiMed
New York
|
+$22.3M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$19.8M |
Top Sellers
| 1 | -$14.5M | |
| 2 | -$12.2M | |
| 3 | -$10.9M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.2M |
| 5 |
Goldman Sachs
New York
|
-$7.18M |